Bio-Techne (FRA:TE1) ROCE %: 12.40% (As of Mar. 2026)


FRA:TE1 Bio-Techne Corp FRA:TE1
83 GF Score
Price €61.94
GF Value €63.22
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Bio-Techne ROCE %?

Bio-Techne FRA:TE1 +24.38% 83 ROCE % is 12.40% as of Mar. 2026. GuruFocus rates FRA:TE1 with a GF Score™ of 83/100 and a GF Value™ of €63.22 (Fairly Valued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bio-Techne's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.40%.

Bio-Techne  (FRA:TE1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bio-Techne ROCE % Related Terms

Bio-Techne ROCE % Historical Data

* Premium members only.

The historical data trend for Bio-Techne's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne ROCE % Chart

Bio-Techne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.78 15.75 14.95 8.00 4.19

Bio-Techne Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.36 -3.29 8.48 8.90 12.40
FRA:TE1
83GF Score
Bio-Techne Corp FRA:TE1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Techne ROCE % Calculation

Bio-Techne's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=92.745/( ( (2511.892 - 148.063) + (2217.672 - 152.461) )/ 2 )
=92.745/( (2363.829+2065.211)/ 2 )
=92.745/2214.52
=4.19 %

Bio-Techne's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=254.748/( ( (2154.385 - 119.924) + (2206.27 - 132.585) )/ 2 )
=254.748/( ( 2034.461 + 2073.685 )/ 2 )
=254.748/2054.073
=12.40 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.40% mean?
Bio-Techne (FRA:TE1) has a ROCE % of 12.40% as of Mar. 2026.
Is Bio-Techne's ROCE % too high?
Bio-Techne's current ROCE % is 12.40%. Overall, Bio-Techne has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's ROCE % compare to ARWR and CYTK?
Bio-Techne's ROCE % of 12.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Bio-Techne's current ROCE % is 12.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (FRA:TE1) is currently considered Fairly Valued. The stock's GF Value™ is €63.22, compared to a current price of €61.94 — trading 2% below its estimated fair value. The current ROCE % is 12.40%. Bio-Techne's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Bio-Techne (FRA:TE1), the current ROCE % is 12.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (FRA:TE1) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of €61.94 is trading 2% below its estimated GF Value™ of €63.22. GuruFocus considers Bio-Techne to be Fairly Valued.

Key valuation signals for FRA:TE1:

  • ROCE %: 12.40%
  • GF Value™: €63.22 vs. price of €61.94 (2% below fair value)
  • GF Score™: 83/100 with 8 warning signs

No single metric tells the full story. See the FRA:TE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
83GF Score

Get the complete analysis for FRA:TE1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€61.94
Price
€63.22
GF Value